498 related articles for article (PubMed ID: 29133568)
1. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.
Wi YM; Greenwood-Quaintance KE; Schuetz AN; Ko KS; Peck KR; Song JH; Patel R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29133568
[TBL] [Abstract][Full Text] [Related]
2. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.
Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP;
Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323
[TBL] [Abstract][Full Text] [Related]
3. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the
Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F;
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa.
Gill CM; Nicolau DP;
J Antimicrob Chemother; 2022 Dec; 78(1):252-256. PubMed ID: 36411249
[TBL] [Abstract][Full Text] [Related]
5. Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing
Soto KD; Alcalde-Rico M; Ugalde JA; Olivares-Pacheco J; Quiroz V; Brito B; Rivas LM; Munita JM; García PC; Wozniak A
Front Cell Infect Microbiol; 2024; 14():1410834. PubMed ID: 38903939
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of MicroScan WalkAway for Determination of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility in Carbapenem-Resistant Gram-Negative Bacilli.
Ito CAS; Bail L; Arend LNVS; Silva KO; Michelotto SS; Nogueira KDS; Tuon FF
J Clin Microbiol; 2021 Nov; 59(12):e0153621. PubMed ID: 34586889
[TBL] [Abstract][Full Text] [Related]
8. Comparison of
Wang L; Zhang X; Zhou X; Yang F; Guo Q; Wang M
Microbiol Spectr; 2023 Jun; 11(3):e0093223. PubMed ID: 37199669
[TBL] [Abstract][Full Text] [Related]
9. Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
Delgado-Valverde M; Portillo-Calderón I; Alcalde-Rico M; Conejo MC; Hidalgo C; Del Toro Esperón C; Pascual Á
Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):445-457. PubMed ID: 38157139
[TBL] [Abstract][Full Text] [Related]
10. [Molecular Analysis of Antibiotic Resistance in CarbapenemResistant Pseudomonas aeruginosa Isolates Isolated from Clinical Samples].
Altan G; Rakici E; Özgümüş OB
Mikrobiyol Bul; 2024 Apr; 58(2):148-170. PubMed ID: 38676583
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
Walkty A; Karlowsky JA; Adam H; Baxter M; Lagacé-Wiens P; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2013 Nov; 57(11):5707-9. PubMed ID: 23939895
[TBL] [Abstract][Full Text] [Related]
12. Nationwide genome surveillance of carbapenem-resistant
Yano H; Hayashi W; Kawakami S; Aoki S; Anzai E; Zuo H; Kitamura N; Hirabayashi A; Kajihara T; Kayama S; Sugawara Y; Yahara K; Sugai M
Antimicrob Agents Chemother; 2024 May; 68(5):e0166923. PubMed ID: 38564665
[TBL] [Abstract][Full Text] [Related]
13. Temporal and geographical prevalence of carbapenem-resistant Pseudomonas aeruginosa and the in vitro activity of ceftolozane/tazobactam and comparators in Taiwan-SMART 2012-2021.
Karlowsky JA; Wise MG; Hsieh TC; Lu HC; Chen WT; Cheng MH; Siddiqui F; Young K; Motyl MR; Sahm DF
J Glob Antimicrob Resist; 2023 Sep; 34():106-112. PubMed ID: 37419182
[TBL] [Abstract][Full Text] [Related]
14. Genomic Surveillance of Clinical Pseudomonas aeruginosa Isolates Reveals an Additive Effect of Carbapenemase Production on Carbapenem Resistance.
Diorio-Toth L; Irum S; Potter RF; Wallace MA; Arslan M; Munir T; Andleeb S; Burnham CD; Dantas G
Microbiol Spectr; 2022 Jun; 10(3):e0076622. PubMed ID: 35638817
[TBL] [Abstract][Full Text] [Related]
15. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
Pan X; Zhao X; Song Y; Ren H; Tian Z; Liang Q; Jin Y; Bai F; Cheng Z; Feng J; Wu W
Microbiol Spectr; 2022 Feb; 10(1):e0267821. PubMed ID: 35196805
[TBL] [Abstract][Full Text] [Related]
16. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
Moya B; Zamorano L; Juan C; Pérez JL; Ge Y; Oliver A
Antimicrob Agents Chemother; 2010 Mar; 54(3):1213-7. PubMed ID: 20086158
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
Cabot G; Ocampo-Sosa AA; Tubau F; Macia MD; Rodríguez C; Moya B; Zamorano L; Suárez C; Peña C; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2011 May; 55(5):1906-11. PubMed ID: 21357294
[TBL] [Abstract][Full Text] [Related]
18.
Castanheira M; Kimbrough JH; Lindley J; Doyle TB; Ewald JM; Sader HS
Antimicrob Agents Chemother; 2024 May; 68(5):e0136323. PubMed ID: 38526050
[TBL] [Abstract][Full Text] [Related]
19. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.
Moyá B; Beceiro A; Cabot G; Juan C; Zamorano L; Alberti S; Oliver A
Antimicrob Agents Chemother; 2012 Sep; 56(9):4771-8. PubMed ID: 22733064
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
Cantón R; Loza E; Arcay RM; Cercenado E; Castillo FJ; Cisterna R; Gálvez-Benítez L; González Romo F; Hernández-Cabezas A; Rodríguez-Lozano J; Suárez-Barrenechea AI; Tubau F; Díaz-Regañón J; López-Mendoza D;
Rev Esp Quimioter; 2021 Jun; 34(3):228-237. PubMed ID: 33645948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
